Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00633386 · ClinicalTrials.gov registry record · Phase 4
Effect of Celecoxib Versus Placebo Before and After Knee Surgery on the Overall Use of Analgesics After Surgery
A Phase 4 study of Arthroscopy, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
- 9
- Study locations
NCT00633386: Completed Phase 4 study of Arthroscopy, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
NCT00633386 is a Phase 4 study of Arthroscopy that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 200 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (61% lower). The trial reports 9 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00633386, a Phase 4 study of Arthroscopy, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
- 9
- Study locations
Study Summary
To compare the total analgesic use at 24 hours after arthroscopic knee surgery in patients treated with celecoxib versus placebo.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Celecoxib
Study Locations (9)
Arizona
- Pfizer Investigational Site - Phoenix
Florida
- Pfizer Investigational Site - St. Petersburg
Maryland
- Pfizer Investigational Site - Baltimore
Massachusetts
- Pfizer Investigational Site - Springfield
Missouri
- Pfizer Investigational Site - Springfield
South Carolina
- Pfizer Investigational Site - Columbia
Tennessee
- Pfizer Investigational Site - Johnson City
Texas
- Pfizer Investigational Site - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2003-02 |
| Est. Completion | 2003-08 |
| Phase | Phase 4 |
What the finished NCT00633386 record still lists
NCT00633386 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Arthroscopy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00633386 lists 9 locations in 9 states (Arizona, Florida, Maryland).
Frequently Asked Questions
What is clinical trial NCT00633386 about?
NCT00633386 is a clinical study titled "Effect of Celecoxib Versus Placebo Before and After Knee Surgery on the Overall Use of Analgesics After Surgery". To compare the total analgesic use at 24 hours after arthroscopic knee surgery in patients treated with celecoxib versus placebo.
What is the current status of trial NCT00633386?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2003-02. Estimated completion is 2003-08.
What conditions does trial NCT00633386 study?
This clinical trial studies the following conditions: Arthroscopy.
What interventions are being tested in trial NCT00633386?
The interventions under investigation include: Placebo (OTHER), Celecoxib (DRUG).
Who is sponsoring clinical trial NCT00633386?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00633386 being conducted?
This trial has 9 study locations across Arizona, Florida, Maryland, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthroscopy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00633386's enrollment target sits among peer trials
200 407th of 2000 higher than 1,557 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia